The biologics omalizumab, mepolizumab, benralizumab, and dupilumab have similar effectiveness in improving lung function in severe asthma.

Increased triglyceride-glucose (TyG) index values are strongly associated with decreased lung function in healthy individuals.

The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but one some analysts see as a “modest” advance in care.

Researchers at National Jewish Health have shown that subtle increases in lung scarring, detected by an artificial intelligence-based tool on CT scans taken one year apart, are associated with disease ...

The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with idiopathic pulmonary fibrosis (IPF). 1 Nerandomilast's approval marks the first for a novel IPF ...